COHEN RICHARD M 4

What Happened
Richard M. Cohen, a director of 20/20 Biolabs, reported the automatic conversion on Feb 19, 2026 of 7,700 shares of Series A‑2 preferred stock into 7,700 shares of common stock (conversion of a derivative). The common shares were recorded as acquired at $0.00, and the derivative (the preferred shares) was reported as disposed. No cash payment was made in the conversion.

Key Details

• Transaction date: February 19, 2026 (period of report).
• Filing date (Form 4): February 23, 2026 (timely filed).
• Shares involved: 7,700 preferred converted into 7,700 common.
• Reported price: $0.00 (no cash consideration).
• Disposal type: conversion of a derivative security (the Series A‑2 preferred).
• Shares owned after transaction: not specified in the provided filing.
• Footnote: The Series A‑2 preferred automatically converted into an equivalent number of common shares upon the issuer's common stock listing on the Nasdaq Capital Market; the Series A‑2 preferred had no expiration date.

Context
This filing records a mechanical corporate conversion tied to the company’s Nasdaq listing rather than an open‑market purchase or sale. Such conversions typically do not indicate a director’s buy/sell decision about the stock; they reflect a change in security type (preferred → common) with no cash exchanged.